Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 09 2023
12 09 2023
Historique:
received:
03
07
2023
accepted:
11
09
2023
medline:
14
9
2023
pubmed:
13
9
2023
entrez:
12
9
2023
Statut:
epublish
Résumé
Systemic sclerosis (SSc) is the most severe systemic autoimmune disease with currently no cure. Intravenous immunoglobulins (IVIg) are an attractive candidate in this disease to counteract inflammation and fibrosis but data are scarce and conflicting. This study, assessed the effects of IVIg in a murine HOCl-induced model of SSc. We showed that IVIg prevented skin inflammation and fibrosis, by mitigating the immune cell infiltration (p = 0.04), proinflammatory cytokines gene overexpression (IL1β, p = 0.04; TNFα, p = 0.04; IL6, p = 0.05), skin and dermal thickening (p = 0.003 at d21 and p = 0.0003 at d42), the expression markers of fibrosis, such as αSMA (p = 0.031 for mRNA and p = 0.05 for protein), collagen (p = 0.05 for mRNA and p = 0.04 for protein, p = 0.05 for the hydroxyproline content) and fibronectin (p = 0.033 for mRNA). Moreover, IVIg prevented HOCl-induced alterations in splenic cell homeostasis. When administered in curative mode, despite their ability to reduce skin and dermal thickness (p < 0.0001 and p = 0.0002), IVIg showed partial or more mixed effects on skin inflammation and established fibrosis. These data favor further clinical trials in SSc patients on the potential efficiency of early and/or repeated IVIg administration.
Identifiants
pubmed: 37700078
doi: 10.1038/s41598-023-42464-9
pii: 10.1038/s41598-023-42464-9
pmc: PMC10497569
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15102Informations de copyright
© 2023. Springer Nature Limited.
Références
Clin Exp Med. 2005 Dec;5(4):135-40
pubmed: 16362793
Autoimmun Rev. 2017 Apr;16(4):377-384
pubmed: 28232167
Nat Rev Immunol. 2013 Mar;13(3):176-89
pubmed: 23411799
Autoimmun Rev. 2021 Dec;20(12):102981
pubmed: 34718166
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):151-6
pubmed: 23910617
Open Access Rheumatol. 2014 Jul 01;6:65-81
pubmed: 27790036
Immunol Res. 2015 Mar;61(3):326-37
pubmed: 25550086
Arch Dermatol Res. 2000 Nov;292(11):535-41
pubmed: 11194891
Arthritis Rheumatol. 2020 Jan;72(1):125-136
pubmed: 31342624
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
Arthritis Rheum. 2004 Mar;50(3):1005-7
pubmed: 15022346
Clin Immunol. 2019 Feb;199:25-28
pubmed: 30543921
Clin Exp Immunol. 2011 Feb;163(2):235-41
pubmed: 21091669
Anat Rec (Hoboken). 2013 Mar;296(3):378-81
pubmed: 23382140
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Autoimmun Rev. 2020 Jan;19(1):102431
pubmed: 31734403
Arthritis Rheum. 2002 Jun;46(6):1689-90
pubmed: 12115202
J Immunol. 2009 May 1;182(9):5855-64
pubmed: 19380834
Clin Immunol. 2010 Jun;135(3):422-9
pubmed: 20138586
Arthritis Rheumatol. 2014 Jul;66(7):1768-78
pubmed: 24644005
J Rheumatol. 2015 Feb;42(2):236-42
pubmed: 25433527
J Dermatol Sci. 2013 Jan;69(1):77-80
pubmed: 23102713
Immunol Res. 2017 Aug;65(4):790-797
pubmed: 28488090